Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares hit a new 52-week low during trading on Thursday . The stock traded as low as $87.95 and last traded at $87.97, with a volume of 1,528,643 shares. The stock had previously closed at $90.75.

ICPT has been the topic of several analyst reports. Wedbush restated an “outperform” rating and set a $231.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, May 26th. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Credit Suisse Group set a $201.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Cowen and Company restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, June 12th. Finally, BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $207.75.

The company’s market capitalization is $2.38 billion. The firm’s 50 day moving average price is $108.47 and its 200 day moving average price is $116.36.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The firm had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same period in the previous year, the company earned ($3.14) earnings per share. The company’s quarterly revenue was up 459.6% on a year-over-year basis. On average, analysts predict that Intercept Pharmaceuticals, Inc. will post ($14.06) earnings per share for the current year.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 394 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.33, for a total value of $47,804.02. Following the transaction, the insider now directly owns 23,619 shares in the company, valued at $2,865,693.27. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Mark Pruzanski sold 40,000 shares of the company’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $130.80, for a total transaction of $5,232,000.00. Following the completion of the transaction, the chief executive officer now owns 611,718 shares in the company, valued at $80,012,714.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 48,013 shares of company stock worth $6,198,747. Corporate insiders own 9.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the business. WFG Advisors LP increased its holdings in shares of Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in shares of Intercept Pharmaceuticals by 85.6% in the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 3,136 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Intercept Pharmaceuticals by 15.0% in the second quarter. Public Employees Retirement System of Ohio now owns 7,385 shares of the biopharmaceutical company’s stock valued at $894,000 after purchasing an additional 965 shares during the last quarter. Asymmetry Capital Management L.P. acquired a new position in shares of Intercept Pharmaceuticals in the second quarter valued at $3,580,000. Finally, Nomura Holdings Inc. acquired a new position in shares of Intercept Pharmaceuticals in the second quarter valued at $366,000. Hedge funds and other institutional investors own 82.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/09/15/intercept-pharmaceuticals-inc-icpt-reaches-new-52-week-low-at-87-95.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.